Authors: Lin M, Gao Y, Deng J.
DOI: 10.3389/fonc.2025.1723763
Abstract Summary
A lung cancer patient with ALK fusion, high PD-L1, and BIM deletion rapidly progressed on two ALK inhibitors (alectinib, lorlatinib). Switching to ivonescimab plus chemotherapy achieved favorable response—the first reported case of this approach. This offers new treatment insights for ALK-positive lung cancer resistant to standard targeted therapies.
Why Brain? 🧠
Novel immunotherapy-chemotherapy combination overcomes resistance in ALK-positive lung cancer after multiple targeted therapy failures, offering new treatment option for difficult-to-treat cases.
License: CC BY.
The image is AI-generated for illustrative purposes only. Courtesy of Midjourney.
